Dyne Therapeutics is a biotechnology company that is focused on developing therapies for patients with genetically driven muscle diseases. The company is developing a platform that is designed to deliver nucleic acids to muscle tissue. Dyne's lead product candidate is DYN101, which is a treatment for patients with myotonic dystrophy type 1 (DM1). DM1 is a genetic disorder that affects the muscles and other body systems. DYN101 is designed to reduce the levels of toxic RNA that are produced by the mutated gene that causes DM1. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.